glp-1 colorectal cancer mortality study november 2025 receptor agonists show anti-cancer benefits beyond weight loss GLP-1 Agents vs Aspirin: A

Liraglutide reduced this renal outcome by 22% after 3.8 years follow up, whereas semaglutide showed a reduction of 36% after 2.1 years

Summary of the Compounded Medication Warning (Mini-List) Compounded semaglutide and tirzepatide are not the same as FDA-approved formulations Salt forms such as semaglutide sodium and semaglutide acetate are not clinically validated Potency, purity, and dosing consistency cannot be guaranteed The FDA has issued multiple warnings regarding safety and legality Taylor Bariatric Institute prescribes only FDA-approved medications from legitimate pharmacies Summary Medical weight loss is most effective when treatment plans are built around safe, proven, FDA-approved medications that target the true physiologic and behavioral drivers of obesity

A user can also report shortages to help inform others

de la Fuente, J

Vaginal oestrogen for prevention of primary urinary tract infections rapid review